BioSpace News Archive

Medifocus Inc. (TSXV-MFS) (“Medifocus” or the “Company”) today announced that Mr. Mirsad Jakubovic has resigned as Chief Financial Officer of the Company.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will be releasing its Fiscal 2020 Third Quarter financial results on Monday August 24th, 2020, before markets open.

PTC Therapeutics, Inc. announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of 49,165 shares of its common stock and 14,175 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to five new employees.

Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company, announced that on August 18, the Compensation Committee of the Company’s Board of Directors approved the grant to 60 new employees of non-qualified stock option awards to purchase an aggregate of 319,200 shares of common stock.

Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the American Society of Clinical Oncology has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.

Nanotechnology drug delivery is a growing field and is witnessing increasing acceptance in health care applications.

Glucose monitoring is a necessary step towards managing diabetes.

Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) (“Kintara” or the “Company”) (Nasdaq: KTRA) announced today that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). On August 19, 2020

New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver fibrosis in NASH patients on treatment for at least 24 months Additional long-term data in PBC highlight the safety and durable efficacy of OCA through six years of open label treatment NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will present at the 2020 Cross-Border Healthcare Webinar Series on Wednesday, August 26, 2020. The Company will present its corporate overview with a focus on: Growth opportunities driven b